Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination

Vaccine

Volumn 27, Issue 38, 2009, Pages 5284-5291

  Aline, Fleur ^a   Brand, Denys ^a   Pierre, Josette ^a   Roingeard, Philippe ^a   Séverine, Munier ^b   Verrier, Bernard ^b   Dimier Poisson, Isabelle ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b INSTITUT DE BIOLOGIE ET CHIMIE DES PROTÉINES   (France)

Author keywords

Dendritic cells; HIV 1; Immunization; p24; PLA nanoparticle; Th1 Th2 balance; Vaccine adjuvant

Indexed keywords

ANION; ANIONIC SURFACTANT; B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NANOPARTICLE; POLYLACTIC ACID;

ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; ADSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGENICITY; ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL THERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXICITY; DENDRITIC CELL; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG UPTAKE; FEASIBILITY STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; INTERFERON PRODUCTION; INTESTINE; LYMPHOCYTE PROLIFERATION; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; CELL LINE; CELL PROLIFERATION; CYTOKINES; DENDRITIC CELLS; FEMALE; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV-1; IMMUNITY, CELLULAR; LACTIC ACID; MICE; MICE, INBRED CBA; NANOPARTICLES; POLYMERS; TH1 CELLS; TH2 CELLS;

EID: 67749142116     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.028     Document Type: Article

References (29)

1. Deeks S.G., and Walker B.D. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27 (2007) 406-416
2. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107 (2006) 4781-4789
3. Ogg G.S., Jin X., Bonhoeffer S., Dunbar P.R., Nowak M.A., Monard S., et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279 (1998) 2103-2106
4. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283 (1999) 857-860
5. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., and Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68 (1994) 6103-6110
6. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68 (1994) 4650-4655
7. Goulder P.J., Phillips R.E., Colbert R.A., McAdam S., Ogg G., Nowak M.A., et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 3 (1997) 212-217
8. Davey Jr. R.T., Bhat N., Yoder C., Chun T.W., Metcalf J.A., Dewar R., et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 96 (1999) 15109-15114
9. Ruiz L., Martinez-Picado J., Romeu J., Paredes R., Zayat M.K., Marfil S., et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 14 (2000) 397-403
10. Oxenius A., Price D.A., Günthard H.F., Dawson S.J., Fagard C., Perrin L., et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci USA 99 (2002) 13747-13752
11. Sinkovics J.G., and Horvath J.C. Vaccination against human cancers. Int J Oncol 16 (2000) 81-96
12. Wierecky J., Mueller M., and Brossart P. Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol Immunother 55 (2006) 63-67
13. Lu W., Arraes L.C., Ferreira W.T., and Andrieu J.M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 10 (2004) 1359-1365
14. García F., Lejeune M., Climent N., Gil C., Alcamí J., Morente V., et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 191 (2005) 1680-1685
15. Ide F., Nakamura T., Tomizawa M., Kawana-Tachikawa A., Odawara T., Hosoya N., et al. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial. J Med Virol 78 (2006) 711-718
16. Connolly N.C., Whiteside T.L., Wilson C., Kondragunta V., Rinaldo C.R., and Riddler S.A. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol 15 (2008) 284-292
17. Aline F., Brand D., Bout D., Pierre J., Fouquenet D., Verrier B., et al. Generation of specific Th1 and CD8+ T-cell responses by immunization with mouse CD8+ dendritic cells loaded with HIV-1 viral lysate or envelope glycoproteins. Microbes Infect 4 (2007) 536-543
18. Elamanchili P., Diwan M., Cao M., and Samuel J. Characterization of poly(d,l-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 22 (2004) 2406-2412
19. Shen H., Ackerman A.L., Cody V., Giodini A., Hinson E.R., Cresswell P., et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 117 (2006) 78-88
20. Ataman-Onal Y., Munier S., Ganee A., Terrat C., Durand P.Y., Battail N., et al. Surfactant-free anionic PLA coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models. J Control Release 112 (2006) 175-185
21. Cheynet V., Verrier B., and Mallet F. Overexpression of HIV-1 proteins in Escherichia coli by a modified expression vector and their one-step purification. Protein Expr Purif 4 (1993) 367-372
22. Jeon H.J., Jeong Y.I., Jang M.K., PArk Y.H., and Nath J.W. Effect of solvent on the preparation of surfactant-free poly(DL-lactide-co-glycolide) nanoparticles and norfloxacin release characterstics. Int J Pharm 207 (2000) 99-108
23. - murine spleen dendritic cell line: establishment, characterization and functional analysis in a model of vaccination to toxoplasmosis. Cell Microbiol 7 (2005) 1659-1671
24. Waeckerle-Men Y., and Groettrup M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev (2005) 475-482
25. Manolova V., Flace A., Bauer M., Schwarz K., Saudan P., and Bachmann M.F. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 38 (2008) 1404-1413
26. Fajardo-Moser M., Berzel S., and Moll H. Mechanisms of dendritic cell-based vaccination against infection. Int J Microbial 298 (2008) 11-20
27. Tacken P.J.I., Jolanda M., de Vries, Ruurd Torensma G., and Figdor C. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 7 (2007) 790-802
28. Lou Q., Conway Jr. T.F., Egilmez N.K., Loyall J.L., Bernstein S.H., Kelleher Jr. R.J., et al. B cell tumor vaccine enhanced by covalent attachment of immunoglobulin to surface proteins on dendritic cells. Clin Immunol 118 (2006) 66-76
29. Lamalle-Bernard D., Munier S., Compagnon C., Charles M.H., Kalyanaraman V.S., Delair T., et al. Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic PLA nanoparticles preserves antigenicity and immunogenicity. J Control Release 115 (2006) 57-67